BGPT: Paper Review: KRAS mutation: from undruggable to druggable in cancer

Explore by Goal

Quick Explanation Copied

Core takeaway: This review argues that KRAS—long treated as “undruggable” because of its nucleotide-pocket physics and smooth surface—became clinically actionable mainly via covalent KRAS(G12C) inhibitors (e.g., sotorasib/AMG 510 and adagrasib/MRTX849), while emphasizing that intrinsic heterogeneity and acquired resistance still limit durable responses and motivate rational combination strategies.

Long Explanation

Paper Review (science-critique): KRAS mutation: from undruggable to druggable in cancer

Signal Transduction and Targeted Therapy (2021). DOI: 10.1038/s41392-021-00780-4

Type Narrative review (no new experiments)

Known vs. claimed (epistemic hygiene)

Known (well-supported by primary/clinical evidence): direct covalent inhibition of KRAS(G12C) emerged as a first validated “druggable” approach and progressed to clinical use (summarized by the review).
Known (mechanistic framework): RAS signaling is a GDP/GTP cycle controlled by GEFs and GAPs, with downstream MAPK and PI3K pathways as major effectors (reviewed background).
Claimed but variable confidence: tumor-microenvironment (TME) and immune modulation by KRAS mutations and by KRAS(G12C) inhibition are summarized broadly; these claims are plausible and supported by multiple preclinical/translation studies in the literature, but the review is not a systematic quantitative synthesis, so effect sizes and context-dependence are not uniform.

1) Visual synthesis of the review’s own quantitative anchors

The paper includes a pan-cancer KRAS mutation frequency table and clinical trial summaries. Below I replot what the paper provides (from its Table 1), to make the hotspot pattern visually inspectable.

Source for plotted numbers: the paper’s Table 1 (TCGA pan-cancer data via cBioPortal).

2) What the review does well (high-signal themes)

A. Mechanistic throughline from “no pockets” → “covalent allostery”

The review’s core organizing idea is that KRAS(G12C) becomes druggable because it creates a chemically addressable switch-II pocket that accommodates electrophilic covalent trapping.

B. Resistance and combinations are framed as “systems problems”

The review emphasizes that monotherapy is limited by intrinsic heterogeneity and acquired resistance, highlighting recurring classes such as pathway rebound/feedback and secondary KRAS mutations, motivating combinations targeting upstream nodes (e.g., RTK/SHP2), downstream nodes (MAPK/PI3K-axis), and the TME.

C. Connects KRAS biology to immune escape (but not quantitatively)

The paper presents multiple mechanistic routes to immune modulation, including PD-L1 regulation and MHC class I downregulation, along with recruitment/polarization of immunosuppressive myeloid populations and Tregs.

3) Critical appraisal (skeptical review)

Limitation 1: It is not a systematic review—selection and emphasis risks

Because this is a narrative review, confidence depends on which studies were highlighted. A key blind spot is the risk of over-weighting positive outcomes and under-weighting negative/failed efforts, especially given the historic “undruggable” narrative and the success of KRAS(G12C) programs. This matters because mechanistic breadth across all KRAS alleles is not guaranteed by the (G12C-specific) success story.

Limitation 2: Cross-tumor translation may be overstated

The review contains statements implying general lessons for combination strategies, but pathway wiring and immune context are known to differ by tissue and by genetic background. Without a standardized cross-trial comparison, “promise” can be directionally correct yet quantitatively misleading.

Limitation 3: Resistance discussion is broad; causal granularity varies

The review organizes resistance into classes (feedback reactivation, bypass signaling, secondary KRAS mutations). However, in real systems, multiple concurrent mechanisms, timing effects, and clonal selection can confound interpretation—especially across preclinical models vs human tumor evolution. The review itself urges further research to identify intrinsic resistance biomarkers.

4) Mechanism-to-therapy logic graph (paper’s conceptual model)

This directed graph compresses the review’s main cause→mechanism→constraint→strategy flow. It is conceptual (not fitted to numerical data).

Source: the conceptual ordering is derived from the review’s summarized narrative around KRAS(G12C) covalent trapping, the resulting pathway suppression, and the listed resistance/combinations.

5) What could falsify the review’s optimistic arc?

Clinical effect collapse: If KRAS(G12C) inhibitor-based regimens fail to produce clinically meaningful objective response and/or survival improvements beyond control arms in adequately powered trials, the “druggable” framing for KRAS would be weakened.
Resistance ubiquity without mitigation: If resistance mechanisms emerge so universally and so quickly that combinations (upstream/downstream/TME/metabolic) do not materially delay or prevent relapse, the strategy of combination-led durability would be undermined.
Biomarker failure: If intrinsic resistance biomarkers cannot be identified robustly (i.e., predictive performance is weak across cohorts), the promise of precision selection (“right patient/right regimen”) becomes less actionable.

6) Buttons for further BGPT deep dives

Author-specific follow-ups (BGPT)

Feedback:

Updated: March 25, 2026